Vol 58, No 2 (2024)
Invited Editorial
Published online: 2024-03-11

open access

Page views 243
Article views/downloads 205
Get Citation

Connect on Social Media

Connect on Social Media

Significance of dysautonomia in Parkinson’s Disease and atypical parkinsonisms

Piotr Alster1, Natalia Madetko-Alster1
Pubmed: 38501557
Neurol Neurochir Pol 2024;58(2):147-149.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Hirsch L, Jette N, Frolkis A, et al. The incidence of parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology. 2016; 46(4): 292–300.
  2. Barer Y, Chodick G, Cohen R, et al. Epidemiology of progressive supranuclear palsy: real world data from the second largest health plan in israel. Brain Sci. 2022; 12(9).
  3. Constantinides VC, Paraskevas GP, Paraskevas PG, et al. Corticobasal degeneration and corticobasal syndrome: a review. Clin Park Relat Disord. 2019; 1: 66–71.
  4. Jellinger KA. Multiple system atrophy: a clinicopathological update. Free Neuropathol. 2020; 1.
  5. Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014; 44(4): 673–683.
  6. Jordan J, Shibao C, Biaggioni I. Multiple system atrophy: using clinical pharmacology to reveal pathophysiology. Clin Auton Res. 2015; 25(1): 53–59.
  7. Schmidt C, Herting B, Prieur S, et al. Autonomic dysfunction in patients with progressive supranuclear palsy. Movement Disorders. 2008; 23(14): 2083–2089.
  8. Altmann CF, Koschel J, Jost WH. Predictors of falls in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a retrospective study. Neurol Neurochir Pol. 2023; 57(3): 297–304.
  9. Koga S, Aiba I. Autonomic Dysfunction in Tauopathies. Brain Nerve. 2022; 74(3): 257–262.
  10. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord. 2022; 37(6): 1131–1148.
  11. Kwaśniak-Butowska M, Dulski J, Pierzchlińska A, et al. Cardiovascular dysautonomia and cognition in Parkinson's Disease: a possible relationship. Neurol Neurochir Pol. 2021; 55(6): 525–535.
  12. Höglinger GU, Respondek G, Stamelou M, et al. Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017; 32(6): 853–864.
  13. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80(5): 496–503.
  14. Kanazawa M, Tada M, Onodera O, et al. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord. 2013; 19(12): 1149–1151.
  15. Yamawaki T. Diagnosis of MSA-P and PSP-P in Early Stage. Brain Nerve. 2020; 72(4): 331–343.
  16. Alster P, Nieciecki M, Migda B, et al. The strengths and obstacles in the differential diagnosis of Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT). Diagnostics (Basel). 2022; 12(2).
  17. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010; 25(3): 357–362.
  18. Malkiewicz JJ, Siuda J. Comparison of autonomic dysfunction in patients with Parkinson's Disease, progressive supranuclear palsy, and multiple system atrophy. Neurol Neurochir Pol. 2023 [Epub ahead of print].
  19. Madetko-Alster N, Otto-Ślusarczyk D, Wiercińska-Drapało A, et al. Clinical phenotypes of progressive supranuclear palsy-the differences in interleukin patterns. Int J Mol Sci. 2023; 24(20).
  20. Holmberg B, Kallio M, Johnels B, et al. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord. 2001; 16(2): 217–225.
  21. Kimber J, Mathias CJ, Lees AJ, et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain. 2000; 123 ( Pt 7): 1422–1430.
  22. Holmberg B, Kallio M, Johnels B, et al. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord. 2001; 16(2): 217–225.
  23. Oliveira MCB, Ling H, Lees AJ, et al. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2019; 90(5): 555–561.
  24. Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1999; 67(5): 620–623.
  25. Nojszewska M, Potulska-Chromik A, Jamrozik Z, et al. Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study. Neurol Neurochir Pol. 2019; 53(1): 26–33.
  26. Pilotto A, Romagnolo A, Scalvini A, et al. Association of orthostatic hypotension with cerebral atrophy in patients with lewy body disorders. Neurology. 2021; 97(8): e814–e824.
  27. Dayan E, Sklerov M, Browner N. Disrupted hypothalamic functional connectivity in patients with PD and autonomic dysfunction. Neurology. 2018; 90(23): e2051–e2058.
  28. Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014; 64(6): 1235–1240.
  29. Przewodowska D, Marzec W, Madetko N. Novel therapies for parkinsonian syndromes-recent progress and future perspectives. Front Mol Neurosci. 2021; 14.
  30. Sławek J, Jost WH. Botulinum neurotoxin in neurological practice: a leading topic in neurology. Neurol Neurochir Pol. 2021; 55(2): 120–124.



Neurologia i Neurochirurgia Polska